Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
IDXG Catalyst Timeline
Dated clinical, regulatory and corporate events for Interpace Biosciences, Inc.
Past FDA Catalysts and PDUFA Decisions
How IDXG actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Drug Pipeline Intelligence
No drug pipeline
Interpace Biosciences, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every IDXG program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Burnell Thomas W.Director, Officer (CEO, President & Chairman) | Option | 1,966,763 2,037,645 held | $0.00 | 08/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in IDXG
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in IDXG for Q2 2026. | ||||
Ownership Trends
IDXG Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How IDXG ranks across every disease it competes in
IDXG News
Interpace Biosciences Announces Third Quarter 2026 Financial and Business Results
Interpace Biosciences reported Q3 2026 revenue of $10.4 million, an 18% increase from the previous year. Despite a loss from continuing operations of $1.5 million, the company achieved a gross margin of 69% and an Adjusted EBITDA of $2.1 million. The results reflect ongoing operational improvements and a focus on thyroid diagnostics.
Read more →Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
Interpace Biosciences anticipates preliminary, unaudited revenue for Q3 2026 to be between $10.1 million and $10.4 million. This represents an 11% to 14% increase from Q2 2026 and a 15% to 18% increase compared to Q3 2025. The final results will be reported after the company's quarter-end closing procedures.
Read more →Interpace Biosciences Announces Reverse Stock Split to Support Proposed Nasdaq Uplisting
Interpace Biosciences announced a 1-for-5 reverse stock split effective August 27, 2026. This move aims to meet Nasdaq's minimum bid price requirement for uplisting. The company will reduce its outstanding shares from approximately 27.7 million to about 5.5 million. The CEO expressed optimism that this strategy will enhance growth and investor interest.
Read more →Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
Interpace Biosciences reported preliminary 2025 thyroid testing revenue of $38-39 million, reflecting a 21% increase from the previous year. The company anticipates a 16% growth in 2026 revenue, totaling around $40 million. Additionally, all preferred stock has been converted to common stock, simplifying the capital structure as Interpace aims for a Nasdaq uplisting.
Read more →